Article Information
History
- July 15, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Victor Carvalho, MD, MSc1,*,
- Ricardo Turon, MD1,2,*,
- Bruno Gonçalves, MD, MSc1,2,3,*,
- Victor Fraga Ceotto, MD1,*,#,
- Pedro Kurtz, MD, PhD2,4 and
- Cássia Righy, MD, PhD2,5,*
- 1Hospital Niterói D’Or, Niterói, RJ, Brazil
- 2Paulo Niemeyer State Brain Institute, Rio de Janeiro, RJ, Brazil
- 3GHU Paris Psychiatrie et Neurosciences, Paris, France
- 4Hospital Copa Star, Rio de Janeiro, RJ, Brazil
- 5Laboratório de Pesquisa Clínica em Medicina Intensiva - Instituto Nacional de Infectologia - Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
- ↵#Corresponding author:
Victor Carvalho MD, Affiliation: Hospital Niterói D’Or, Niterói, RJ, Brazil, torcortes{at}yahoo.com.br, +55 21 984310953
↵* (contributed equally)
Posted July 15, 2020.
Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study
